A case of metformin-associated encephalopathy in a patient undergoing maintenance hemodialysis
Abstract
Metformin is a major drug for the treatment of type 2 diabetes mellitus; however, its use is not recommended in dialysis patients due to the risk of lactic acidosis. Consequently, there are very few reports of metformin-associated lactic acidosis (MALA) or metformin-associated encephalopathy in dialysis patients. We report a case of a 67-year-old man undergoing maintenance hemodialysis who was admitted to our hospital with impaired consciousness. Blood tests revealed marked hypoglycemia (blood glucose level of 18 mg/dL) in addition to severe metabolic acidosis and lactic acidosis (pH 6.989, HCO3- 5.8 mmol/L, and lactate 10.7 mmol/L). The patient had a history of metformin use, and was diagnosed with MALA. We immediately initiated glucose correction and emergency hemodialysis. On the same day, magnetic resonance imaging (MRI) showed symmetrical swelling in the bilateral basal ganglia, with low signal intensity on T1-weighted images and high signal intensity on T2-weighted and fluid-attenuated inversion recovery images, leading to a diagnosis of metformin-associated encephalopathy. The patient's condition improved with frequent dialysis sessions, and subsequent MRI showed improvement in the lesions. The patient was discharged on the 17th day, after confirming recovery to the pre-admission level. The present case reinforces the recommendation that metformin should not be prescribed to patients undergoing dialysis.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.